DelistingNov 12, 2026, 04:24 PM
Rani Therapeutics Gets 180-Day Extension to Meet Nasdaq Bid Price Rule
AI Summary
Rani Therapeutics Holdings, Inc. has been granted an extension until May 10, 2027, to meet Nasdaq's minimum $1.00 closing bid price requirement. The company's listing was transferred to The Nasdaq Capital Market, effective November 12, 2026. To regain compliance, Rani Therapeutics must achieve a closing bid price of at least $1.00 for 10 consecutive business days. The company is exploring options, such as a reverse stock split, to address the deficiency, though there is no assurance of success.
Key Highlights
- Rani Therapeutics Holdings, Inc. received an additional 180 days, until May 10, 2027, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
- The company's listing was transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 12, 2026.
- Rani Therapeutics must maintain a closing bid price of at least $1.00 per share for 10 consecutive business days to regain compliance.
- The company met other Nasdaq listing requirements, including market value of publicly held shares.
- Rani Therapeutics is evaluating options to regain compliance, potentially including a reverse stock split.
Price Impact
More from RANI